BRIEF-Novo Nordisk Says New Phase 2 Data For Somapacitan Demonstrate Its Potential

by Reuters
Friday, 28 September 2018 06:45 GMT

Sept 28 (Reuters) - Novo Nordisk A/S:

* NOVO NORDISK A/S - NEW PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE ITS POTENTIAL AS AN EFFICACIOUS ONCE-WEEKLY TREATMENT FOR CHILDHOOD GROWTH HORMONE DEFICIENCY Source text for Eikon: Further company coverage: (Copenhagen newsroom)

Our Standards: The Thomson Reuters Trust Principles.